Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2017 05/19/2017 05/22/2017 05/23/2017 05/24/2017 Date
89.99(c) 89.23(c) 90.49(c) 88.36(c) 87.96 Last
1 192 983 700 160 731 641 881 456 775 242 Volume
+0.25% -0.84% +1.41% -2.35% -0.45% Change
More quotes
Financials ($)
Sales 2017 1 278 M
EBIT 2017 -145 M
Net income 2017 -142 M
Debt 2017 44,8 M
Yield 2017 -
Sales 2018 1 487 M
EBIT 2018 -39,5 M
Net income 2018 -61,9 M
Debt 2018 50,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 12,1x
EV / Sales2018 10,4x
Capitalization 15 418 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
06/06Shareholder meeting
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
05/09 BIOMARIN PHARMACEUTICAL : Biotech Stocks on Investors' Radar -- BioMarin Pharma,..
05/05 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) reported earnings of $0.20 per shar..
05/04 BIOMARIN PHARMACEUTICAL : FDA Approves Brineura cerliponase alfa for the Treatme..
05/04 BIOMARIN PHARMACEUTICAL : reports 1Q loss
05/04 BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
05/04 BIOMARIN PHARMACEUTICAL : Receives Positive CHMP Opinion in Europe for Brineura ..
05/04 BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
05/04 BIOMARIN PHARMACEUTICAL INC. : Investor Network: BioMarin Pharmaceutical Inc. to..
05/02 BIOMARIN PHARMACEUTICAL : to Attend Two Upcoming Investor Conferences
04/28 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) Scores Big, But Have The Children?
More news
Sector news : Biopharmaceuticals
07:35p JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
06:10p FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Biopharmaceuticals
Latest Tweets
04:42aDai Ichi Life Insurance Company Ltd Acquires 2,780 Shares of BioMarin Pharmac.. 
05/23Karp Capital Management Corp Buys Shares of 51,485 BioMarin Pharmaceutical In.. 
05/23Jean Jacques Bienaime Sells 5,000 Shares of BioMarin Pharmaceutical Inc. $BMR.. 
05/23BioMarin Pharmaceutical Inc. $BMRN Position Raised by NN Investment Partners .. 
05/20BioMarin Pharmaceutical Inc. $BMRN Receives $110.51 Consensus PT from Analyst.. 
More tweets
Qtime:111
News from SeekingAlpha
05/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
05/19 BioMarin Pharmaceutical (BMRN) Bank of America Merrill Lynch 2017 Health Care..
05/12 Sangamo's Gene Therapy Gets Pfizer Stamp Of Approval
05/05 BioMarin Pharmaceutical (BMRN) Q1 2017 Results - Earnings Call Transcript
05/04 BioMarin Pharmaceutical misses by $0.08, beats on revenue
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 113 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..6.66%15 790
BIOGEN INC-5.06%53 037
CSL LIMITED29.74%44 135
ALEXION PHARMACEUTICAL..-14.47%25 918
GRIFOLS SA33.77%17 672
CHONGQING ZHIFEI BIOLO..--.--%4 422
More Results